Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Revenue (2019 - 2025)

Historic Revenue for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $13.6 million.

  • Nurix Therapeutics' Revenue rose 220.57% to $13.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $84.0 million, marking a year-over-year increase of 5395.33%. This contributed to the annual value of $84.0 million for FY2025, which is 5395.33% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Revenue of $13.6 million as of Q4 2025, which was up 220.57% from $7.9 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Revenue peaked at $44.1 million during Q2 2025, and registered a low of $5.0 million during Q1 2021.
  • Moreover, its 5-year median value for Revenue was $12.3 million (2024), whereas its average is $14.2 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Revenue crashed by 6058.16% in 2024, and later surged by 26434.01% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Revenue (Quarter) stood at $7.4 million in 2021, then dropped by 8.29% to $6.8 million in 2022, then soared by 123.49% to $15.2 million in 2023, then fell by 12.37% to $13.3 million in 2024, then rose by 2.21% to $13.6 million in 2025.
  • Its last three reported values are $13.6 million in Q4 2025, $7.9 million for Q3 2025, and $44.1 million during Q2 2025.